Amgen Clinches $900M to Accelerate Next-Generation Biotech Innovations

Amgen is thrilled to announce a major milestone in our journey to revolutionize healthcare innovation by raising 900,000,000 in funding. As a global leader at the frontier of biotechnology, we harness the best of biology and technology to fight the world’s toughest diseases and improve quality of life for millions. This significant capital infusion will be strategically allocated to bolster our already robust pipeline of medicines, facilitating groundbreaking research and development in areas such as cancer, heart disease, osteoporosis, inflammatory diseases, and rare disorders. By deepening our investment in new technologies and human genetic data, we are committed to pushing the boundaries of what’s known and achieving breakthroughs that could redefine medical care. This funding marks a pivotal step forward in our long legacy of innovation that helped to establish the biotechnology industry, solidifying our reputation as one of the world’s most innovative companies—a distinction recognized by Fast Company in 2024—and as one of America’s Best Large Employers by Forbes. As one of only 30 companies in the Dow Jones Industrial Average® and a key component of the Nasdaq-100 Index®, our progress is underpinned by a blend of scientific expertise, technological advancement, and a passionate commitment to improving lives. With these new resources, Amgen will accelerate efforts in clinical trials and expand existing research initiatives, ultimately leading to more effective therapies and a healthier future for patients worldwide. We invite our community, partners, and supporters to stay updated on our progress by following us on X, LinkedIn, Instagram, TikTok, YouTube, and Threads. For additional information, please visit Amgen.com.